It appears Micron has stumbled, quite fortuitously, into the artificial intelligence arena. Their dynamic random-access memory (DRAM) and NAND flash memory, bless their little silicon hearts, are proving rather essential to these newfangled AI accelerators. From graphics cards to central processing units – a veritable bonanza, wouldn’t you say?
The divestiture, a transaction valued at approximately $74.50 million, wasn’t announced with trumpets or pronouncements, but rather materialized as a subtle shift in the constellations of ownership. It was a withdrawal, a pulling back of funds, as if sensing a change in the atmospheric pressure, a premonition of winds shifting direction. The numbers, of course, were precise – the shares unloaded, the value diminished – but they failed to capture the essence of the gesture, the quiet deliberation behind the act of letting go.
A favourable report concerning their earnings in February did, indeed, occasion a momentary enthusiasm, though it proved, as is so often the case, a fleeting joy. The subsequent session witnessed a regrettable decline, a reminder that even the most promising ventures are subject to the whims of the market. However, a recovery has since been effected, and the stock now stands at an increase of approximately twenty-two percent from the year’s beginning, a circumstance which invites a closer inspection.
The filing, dated February 17th, confirms the purchase. A bold stroke, considering Navan’s recent performance. The shares, having floated some months ago at $25, currently trade at a shade over $10. A decline of sixty per cent. The sort of figure that usually precipitates a rout, or at least a particularly gloomy luncheon. That Greenoaks should venture in at this juncture suggests either a remarkable degree of conviction, or a lamentable lack of memory.
Payments were up 17% to $396 million. Solid. Platform-related activity? A whopping 47% increase to $200 million. Which, translated from corporate-speak, means they’re finding new and creative ways to extract fees. It’s a beautiful system, really. Like a Rube Goldberg machine designed to separate fools from their money. And the net loss? Oh, it doubled. To $45 million. That’s right, they’re losing more money faster. But don’t worry, the analysts were expecting worse. Bless their hearts. They’re paid to look at the glass half-empty, then write a poem about it.
The filing, dated February 17, 2026, confirms the purchase. TTM Technologies, it appears, has enjoyed a year of exceptional, almost indecent, prosperity. The share price has, rather improbably, tripled. A 250% gain in twelve months is, shall we say, unusual. One suspects a degree of speculative fervour is at play, a condition rarely conducive to long-term investment.
According to a filing with the U.S. Securities and Exchange Commission – a document so densely worded it could likely be used as a structural component in a small building – Metavasi Capital offloaded its 37,000 shares in Wix.com. This resulted in a paper loss of $6.57 million. Which, while regrettable, is considerably less than the estimated cost of replacing all the lost socks in the known universe. (A figure we’re still calculating, naturally.)
One observes, with a degree of quiet anticipation, the trajectory of Amazon. It seems, to this observer, that the company is poised to join this select group. Artificial intelligence, that restless spirit of our age, is indeed fueling growth within Amazon Web Services, its cloud division. And the e-commerce business, once characterized by a relentless pursuit of volume, is exhibiting a welcome increase in profitability, a testament to the efficiencies now woven into its logistical network.
The company released its fourth-quarter and full-year 2025 financials prior to the market’s opening. Revenue registered an increase of forty-six percent year over year, reaching just under $112 million. However, a closer inspection reveals the scaffolding upon which this figure rests. Nearly $22.9 million originates from the sales of Furoscix, an edema treatment acquired through the assimilation of scPharmaceuticals in October of the same year. This acquisition, while presented as expansion, feels more akin to a patching of vulnerabilities, a temporary bolstering of a potentially weakening edifice.
